Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04, Zacks reports. The business had revenue of $69.11 million for the quarter, compared to analysts' expectations of $61.58 million.
Esperion Therapeutics Stock Performance
Shares of NASDAQ:ESPR traded up $0.10 during midday trading on Friday, reaching $1.69. 3,260,581 shares of the company's stock traded hands, compared to its average volume of 4,053,618. The company has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $2.08. Esperion Therapeutics has a 1 year low of $1.56 and a 1 year high of $3.94. The company has a market cap of $332.99 million, a P/E ratio of -2.64 and a beta of 1.01.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on ESPR. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of "Hold" and an average price target of $6.75.
Get Our Latest Analysis on ESPR
About Esperion Therapeutics
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Stories
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
